CJC-1295 and sermorelin are the closest relatives in the whole growth hormone-releasing hormone family, closer than either is to tesamorelin. They are built on the identical 29-amino-acid backbone. Everything that separates them was added deliberately, substitution by substitution, to solve one problem: the native sequence does not survive long enough in blood to be a practical research tool. Comparing them is therefore a story about degradation and the engineering against it.
The shared starting point
Native human GHRH is 44 amino acids long, and its full activity lives in the first 29. That fragment, GHRH(1-29), binds the GHRH receptor on pituitary somatotrophs and triggers growth hormone release exactly as the full hormone does.
Sermorelin simply is that fragment, synthesised as the acetate salt. Nothing is modified. That fidelity to the natural sequence made it attractive historically, and it held FDA approval as Geref for paediatric growth hormone deficiency and diagnostic use before being withdrawn from the market in 2008 for commercial rather than safety reasons, a history we cover in more depth in Tesamorelin vs Sermorelin.
The cost of the natural sequence is fragility. Dipeptidyl peptidase-4 cleaves it within minutes at the N-terminal end, and the kidneys filter what remains, giving sermorelin a circulating half-life reported around 10 to 20 minutes. The growth hormone pulse it provokes is correspondingly sharp and brief, which is precisely what made it useful as a diagnostic probe of pituitary function.
What CJC-1295 changes
CJC-1295 takes the same 29 residues and makes four substitutions: D-alanine at position 2, glutamine at position 8, alanine at position 15 and leucine at position 27. The D-alanine blocks the DPP-4 cleavage site; the others address oxidation and other degradation routes. The result, often called modified GRF(1-29) in its unconjugated form, holds the receptor like sermorelin but survives meaningfully longer.
The full CJC-1295 molecule then adds the Drug Affinity Complex, a maleimide group that covalently couples the peptide to serum albumin after injection, extending its life from minutes to the better part of a week. Teichman and colleagues measured growth hormone and IGF-1 elevation persisting up to 14 days after single doses in healthy adults. The two versions of the molecule, and why the DAC matters, get their own article in CJC-1295 DAC vs no DAC.
So the comparison with sermorelin runs: identical receptor, identical active backbone, and a half-life difference of roughly three orders of magnitude at the far end.
Signal shape, again
The half-life difference is not a convenience detail; it changes the physiology being studied. Sermorelin's pulse mimics a single endogenous GHRH burst, leaving the somatostatin feedback loop in charge between doses. CJC-1295 with DAC applies continuous receptor pressure, and Ionescu and Frohman's finding that pulsatile growth hormone secretion persists on top of an elevated baseline during continuous exposure is the key piece of physiology for interpreting any protocol built on it.
Research questions therefore sort the two molecules cleanly. Work that needs a transient, physiological stimulus, or the diagnostic logic of provoke-and-measure, is sermorelin-shaped. Work that needs sustained elevation of the axis without daily intervention is CJC-1295-shaped. Neither can substitute for the other without changing the experiment.
The evidence records are both thin, differently
Sermorelin's record is old but regulatory-grade: a genuine approval, decades of diagnostic use, and a safety history from that era. Its modern literature, however, is thin, and much of what circulates derives from compounding practice rather than controlled trials.
CJC-1295's record is modern but small: careful pharmacokinetic and hormone-response studies in healthy adults from the mid-2000s, and then a halted development programme with no approval anywhere. Neither compound carries a modern phase 3 dataset; in this family only tesamorelin does.
The takeaway
Sermorelin is the natural fragment, fast in and fast out; CJC-1295 is the same fragment armoured against degradation, and in its DAC form anchored to albumin for a multi-day signal. Same receptor, same backbone, different clocks. The choice between them in a research setting is a choice about signal duration first and about evidence vintage second. Both are supplied for research in defined formats, including the CJC-1295 with DAC vial and the CJC-1295 nasal spray, each verified by certificate of analysis.
All products are intended for research use only. Not for human consumption. Must be 21 years of age or older to purchase.
References
1. Teichman, S. L., Neale, A., Lawrence, B., et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, 91(3), 799-805.
2. Prakash, A., & Goa, K. L. (1999). Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs, 12(2), 139-157.
3. Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism, 91(12), 4792-4797.
